Dr. Stephen Reeders
Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.
Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas's Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.
Steve is a member of the boards of Cheetah Medical, Inc., and Pulmagen Therapeutics Ltd. He was previously a director of Beacon Endoscopic Ltd., BioVex Group, Inc., Biomedix, Inc., Cara Therapeutics, Inc., Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd, Sangamo Biosciences, Inc., Spherics, Inc., UpToDate, Inc. Xention Ltd and Vascular Pathways, Inc.